News & Events
“We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.”
TikoMed appoints Dr Björn Pilström as new Chief Executive, Henrik Otendal returns to CFO role.
30 september 2025
TikoMed’s Board of Directors has appointed Dr Björn Pilström as Chief Executive Officer of TikoMed. Dr Pilström has an MD…
Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, and will include 116 patients over a 12-month study period.
15 augusti 2025
Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind…
TikoMed elects a new Board of Directors – Annika Kollén and Anders Svensson join the board
10 juli 2025
At the Annual General Meeting on 30 June 2025, TikoMed elected a new board of directors for the period until…
TikoMed väljer ny styrelse – Annika Kollén och Anders Svensson in i styrelsen
10 juli 2025
Vid den ordinarie bolagsstämman den 30 juni 2025 valde TikoMed en ny styrelse för tiden fram till nästa bolagsstämma. De…
TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.
22 juli 2024
Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed…
The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed have officially signed a research collaboration agreement.
27 juni 2024
Oslo, June 25th, 2024. The Division of Clinical Neuroscience at Oslo University Hospital and the Swedish drug development company TikoMed…
Prominent Italian ALS expert Adriano Chiò joins TikoMed’s Scientific Advisory Board (SAB)
25 oktober 2023
Viken, Sweden – October 25, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Adriano Chiò,…
TikoMed appoints leading ALS expert Jeremy Shefner, Barrow Neurological Institute, Phoenix, Arizona to its Scientific Advisory Board (SAB)
11 oktober 2023
Viken – October 11, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Professor Jeremy Shefner, MD,…
TikoMed announces the appointment of prominent Karolinska ALS authority Caroline Ingre to its Scientific Advisory Board (SAB)
26 september 2023
Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior…